• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    7/24/24 4:30:06 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    QuidelOrtho Corporation

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    219798105

    (CUSIP Number)

     

    Jeffrey Ferguson

    The Carlyle Group

    1001 Pennsylvania Avenue, NW

    Suite 220 South

    Washington, D.C. 20004

    (202) 729-5626

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 23, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 219798105 13D Page 1 of 13 pages

     

    1

    Names of Reporting Persons

     

    The Carlyle Group Inc.

     
    2

    Check the Appropriate Box if a Member of a Group

     

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    CO

     

     

     

     

    CUSIP No. 219798105 13D Page 2 of 13 pages

     

    1

    Names of Reporting Persons

     

    Carlyle Holdings II GP L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 3 of 13 pages

     

    1

    Names of Reporting Persons

     

    Carlyle Holdings II L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

     

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 4 of 13 pages

     

    1

    Names of Reporting Persons

     

    CG Subsidiary Holdings L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

     

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 5 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group Cayman Investment Holdings, L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 6 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group Cayman Investment Holdings Sub L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 7 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group VI Cayman, L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 8 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group VI Cayman, L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 9 of 13 pages

     

    1

    Names of Reporting Persons

     

    Carlyle Partners VI Cayman Holdings, L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    10,327,772

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    10,327,772

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,327,772

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    15.4%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 10 of 13 pages

     

    Explanatory Note

     

    This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) amends and supplements the statement on Schedule 13D filed with the United States Securities and Exchange Commission (the “SEC”) on June 6, 2022 (the “Schedule 13D”), relating to the common stock, par value $0.001 per share (the “Common Stock”), of QuidelOrtho Corporation, a Delaware corporation (the “Issuer”), whose principal executive office is located at 9975 Summers Ridge Road, San Diego, California 92121. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

     

     

     

     

    CUSIP No. 219798105 13D Page 11 of 13 pages

     

    Item 5.Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 66,971,816 shares of Common Stock outstanding as of May 1, 2024, as disclosed in the Issuer’s quarterly report on Form 10-Q filed on May 9, 2024.

     

    Reporting Person 

    Amount

    beneficially

    owned

      

    Percent

    of class

       Sole power to vote or to direct the vote   Shared power to vote or to direct the vote   Sole power to dispose or to direct the disposition   Shared power to dispose or to direct the disposition 
    The Carlyle Group Inc.   10,327,772    15.4%    0    10,327,772        0    10,327,772 
    Carlyle Holdings II GP L.L.C.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    Carlyle Holdings II L.L.C.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    CG Subsidiary Holdings L.L.C.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    TC Group Cayman Investment Holdings, L.P.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    TC Group Cayman Investment Holdings Sub L.P.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    TC Group VI Cayman, L.L.C.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    TC Group VI Cayman, L.P.   10,327,772    15.4%   0    10,327,772    0    10,327,772 
    Carlyle Partners VI Cayman Holdings, L.P.   10,327,772    15.4%   0    10,327,772    0    10,327,772 

     

    Reflects shares of Common Stock held of record by Carlyle Partners VI Cayman Holdings, L.P. The Carlyle Group Inc., a publicly traded company listed on Nasdaq, is the sole member of Carlyle Holdings II GP L.L.C., which is the managing member of Carlyle Holdings II L.L.C., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the general partner of TC Group Cayman Investment Holdings, L.P., which is the general partner of TC Group Cayman Investment Holdings Sub L.P., which is the sole member of TC Group VI Cayman, L.L.C., which is the general partner of TC Group VI Cayman, L.P., which is the general partner of Carlyle Partners VI Cayman Holdings, L.P. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Carlyle Partners VI Cayman Holdings, L.P., but each disclaims beneficial ownership of such securities.

     

     

     

     

    CUSIP No. 219798105 13D Page 12 of 13 pages

     

    (c) From July 12, 2024 through July 23, 2024, pursuant to the 10b5-1 Plan, Carlyle Partners VI Cayman Holdings, L.P. disposed of 717,230 shares of Common Stock in a series of open-market transactions. Details by date, listing the number of shares of Common Stock disposed of and the weighted average price per share, are provided below. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for each transaction.

     

    Date   Shares Disposed Of   Price Range   Weighted Average Price Per Share
    July 12, 2024   4,722   $31.36 to $31.99   $31.7063
    July 12, 2024   52,531   $32.02 to $32.70   $32.4089
    July 15, 2024   90,507   $31.3251 to $31.996   $31.6896
    July 15, 2024   2,680   $32.00 to $32.2993   $32.1535
    July 16, 2024   6,736   $31.47 to $31.9984   $31.7621
    July 16, 2024   25,995   $32.00 to $32.9973   $32.309
    July 16, 2024   47,839   $33.00 to $33.999   $33.5203
    July 16, 2024   14,291   $34.00 to $34.18   $34.13
    July 17, 2024   65,670   $34.03 to $34.9996   $34.7927
    July 17, 2024   3,967   $35.00 to $35.08   $35.0343
    July 18, 2024   53,224   $33.1529 to $33.9966   $33.4592
    July 18, 2024   32,989   $34.0077 to $34.99   $34.7526
    July 18, 2024   15,657   $35.00 to $35.24   $35.0852
    July 19, 2024   1,500   $32.93   $32.93
    July 19, 2024   21,182   $33.0036 to $33.9998   $33.5406
    July 19, 2024   42,954   $34.00 to $34.81   $34.4528
    July 22, 2024   6,202   $34.8854 to $34.9961   $34.9597
    July 22, 2024   129,039   $35.00 to $35.7493   $35.3292
    July 23, 2024   8,814   $35.125 to $35.9993   $35.5778
    July 23, 2024   84,892   $36.00 to $36.9995   $36.5844
    July 23, 2024   5,839   $37.00 to $37.07   $37.0242

     

    (d) None.

     

    (e) Not applicable.

     

     

     

     

    CUSIP No. 219798105 13D Page 13 of 13 pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: July 24, 2024

     

      The Carlyle Group Inc.
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Chief Financial Officer
         
      Carlyle Holdings II GP L.L.C.
       
      By: The Carlyle Group Inc., its sole member
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Chief Financial Officer
         
      Carlyle Holdings II L.L.C.
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      CG Subsidiary Holdings L.L.C.
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      TC Group Cayman Investment Holdings, L.P.
       
      By: CG Subsidiary Holdings L.L.C., its general partner
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      TC Group Cayman Investment Holdings Sub L.P.
       
      By: TC Group Cayman Investment Holdings, L.P., its general partner
      By: CG Subsidiary Holdings L.L.C., its general partner
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      TC Group VI Cayman, L.L.C.
         
      By: /s/ Jeremy W. Anderson
      Name: Jeremy W. Anderson
      Title: Vice President
         
      TC Group VI Cayman, L.P.
       
      By: TC Group VI Cayman, L.L.C., its general partner
         
      By: /s/ Jeremy W. Anderson
      Name: Jeremy W. Anderson
      Title: Vice President
         
      Carlyle Partners VI Cayman Holdings, L.P.
       
      By: TC Group VI Cayman, L.P., its general partner
      By: TC Group VI Cayman, L.L.C., its general partner
         
      By: /s/ Jeremy W. Anderson
      Name: Jeremy W. Anderson
      Title: Vice President

     

     

    Get the next $QDEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/7/2026$12.50Buy → Hold
    Jefferies
    10/7/2025$33.00Buy → Neutral
    Citigroup
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    More analyst ratings

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cell

    6/2/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    When Blood Compatibility Becomes a Pregnancy Risk

    SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibo

    5/21/26 9:18:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences

    SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m. PT.Jefferies Global Healthcare Conference, Wednesday, June 3, 2026Members of QuidelOrtho's management team will participate in a fireside

    5/20/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Strobeck Matthew was granted 6,829 shares, increasing direct ownership by 25% to 34,604 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/2/26 4:11:11 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Widder Kenneth J was granted 6,829 shares, increasing direct ownership by 18% to 43,890 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/2/26 4:10:48 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Polan Mary Lake Ph D was granted 6,829 shares, increasing direct ownership by 54% to 19,469 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/2/26 4:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    SEC Filings

    View All

    SEC Form SD filed by QuidelOrtho Corporation

    SD - QuidelOrtho Corp (0001906324) (Filer)

    5/11/26 4:05:44 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    5/7/26 10:42:02 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    5/6/26 5:13:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 12:44:31 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho downgraded by Jefferies with a new price target

    Jefferies downgraded QuidelOrtho from Buy to Hold and set a new price target of $12.50

    5/7/26 8:02:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho downgraded by Citigroup with a new price target

    Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $33.00

    10/7/25 8:58:45 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

    – Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and

    4/20/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho Reports First Quarter 2026 Financial Results

    ― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ―― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results:(all comparisons are to the prior year period)Total revenue was $620

    5/5/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TTP Group Announces the Sale of LEX Diagnostics

    TTP today announced the acquisition by QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular testing platform capable of delivering PCR results in minutes. "At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care," said Dr Andrew Baker-Campbell, Chair and f

    4/20/26 7:56:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance

    SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 RevenueThe Company currently expects preliminary unaudited revenue, as reported, o

    4/15/26 4:15:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care